Uh oh... There goes Invitrogen

My prediction on Invitrogen (Ticker: IVGN) beating the numbers was a bit off. Well, way off! The company reported earnings per share of $0.90 versus consensus of $0.85, but the company missed on the revenue numbers. The shares are currently trading down 9% in after hours. We’ll see what the company says on the conference call. The company is also initiating a $500 million share buy back. I still like this company and if the market over reacts to this news, I’ll pick up a few shares.